{"id":1465,"date":"2021-06-08T15:00:37","date_gmt":"2021-06-08T18:00:37","guid":{"rendered":"https:\/\/petrusraulino.com.br\/?p=1465"},"modified":"2024-11-11T17:19:50","modified_gmt":"2024-11-11T20:19:50","slug":"potassium-ion-channel-modulation-for-the-treatment-of-depression","status":"publish","type":"post","link":"https:\/\/petrusraulino.com.br\/en\/potassium-ion-channel-modulation-for-the-treatment-of-depression\/","title":{"rendered":"Potassium ion channel modulation for the treatment of depression?"},"content":{"rendered":"

By Dr. Petrus Raulino<\/strong><\/em><\/p>\n

A new study by Icahn School of Medicine Mount Sinai<\/em> and published in <\/span>American Journal of Psychiatry <\/span><\/i>showed that ezogabine, a drug that opens KCNQ2\/3 potassium channels in the brain, may be associated with an improvement in depressive symptoms and anhedonia.<\/span><\/p>\n

This is a phase 2 study, so it doesn't yet serve as a recommendation for changes in medical practice. However, it does encourage further phase 3 research that could support interventions in clinical practice.<\/span><\/p>\n

Ezogabine has been approved by Food and Drug Administration<\/em> in the US in 2011 as an anticonvulsant for the treatment of epilepsy, but had not previously been studied in depression.\u00a0<\/span><\/p>\n

This study is the first randomized clinical trial <\/span>to show that a drug that affects this type of ion channel in the brain can improve depressive symptoms.<\/span><\/p>\n

The study was carried out with 45 adult patients diagnosed with depression who underwent a 5-week period of treatment with a daily dose of ezogabine or placebo.<\/span><\/p>\n

Compared to patients treated with placebo, those treated with ezogabine showed a significant reduction in several important symptoms of depression, including anhedonia.<\/span><\/p>\n

The target of ezogabine is the KCNQ2\/3 channel, which is a member of a large family of ion channels that act as important controllers of brain cell excitability and central nervous system function.\u00a0<\/span><\/p>\n

These channels affect the function of brain cells by controlling the flow of electrical charge across the cell membrane in the form of potassium ions (K+).<\/span><\/p>\n

The research findings could represent a new line of research for the development of new and effective treatments for depression.<\/span><\/p>\n

 <\/p>\n

References<\/h4>\n

Costi, S., Morris, L. S., Kirkwood, K. A., Hoch, M., Corniquel, M., Vo-Le, B., ... & Murrough, J. W. (2021). Impact of the KCNQ2\/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression: results from a randomized controlled trial.\u00a0<\/span>American Journal of Psychiatry<\/span><\/i>, appi-ajp.<\/span><\/p>\n

Stafstrom, C. E., Grippon, S., & Kirkpatrick, P. (2011). Ezogabine (retigabine).\u00a0<\/span>Nature Reviews Drug Discovery<\/span><\/i>,\u00a0<\/span>10<\/span><\/i>(10), 729-730.<\/span><\/p>","protected":false},"excerpt":{"rendered":"

By Dr. Petrus Raulino A new study developed by the Icahn School of Medicine Mount Sinai and published in the American Journal of Psychiatry has shown that ezogabine, a drug that opens KCNQ2\/3-type potassium channels in the brain, may be associated with an improvement in depressive symptoms and anhedonia. The study is a phase 2 study, [...]<\/p>","protected":false},"author":4,"featured_media":1478,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_joinchat":[],"footnotes":""},"categories":[127,115,117,129],"tags":[],"class_list":["post-1465","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biologia-e-saude-mental","category-informativo","category-transtornos-psicologicos","category-tratamentos"],"yoast_head":"\nModula\u00e7\u00e3o do canal i\u00f4nico de pot\u00e1ssio para depress\u00e3o?<\/title>\n<meta name=\"description\" content=\"Estudo mostra que ezogabina, um f\u00e1rmaco que abre canais de pot\u00e1ssio no c\u00e9rebro, pode estar associada \u00e0 melhora de sintomas depressivos.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/petrusraulino.com.br\/en\/potassium-ion-channel-modulation-for-the-treatment-of-depression\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Modula\u00e7\u00e3o do canal i\u00f4nico de pot\u00e1ssio para tratamento da depress\u00e3o?\" \/>\n<meta property=\"og:description\" content=\"Estudo mostra que ezogabina, um f\u00e1rmaco que abre canais de pot\u00e1ssio no c\u00e9rebro, pode estar associada \u00e0 melhora de sintomas depressivos.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/petrusraulino.com.br\/en\/potassium-ion-channel-modulation-for-the-treatment-of-depression\/\" \/>\n<meta property=\"og:site_name\" content=\"Dr. Petrus Raulino\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/drpetrusraulinopsiquiatriaclinica\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-08T18:00:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-11T20:19:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/petrusraulino.com.br\/wp-content\/uploads\/2021\/06\/modulacao.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1447\" \/>\n\t<meta property=\"og:image:height\" content=\"868\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Petrus Raulino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Petrus Raulino\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Potassium ion channel modulation for depression?","description":"A study shows that ezogabine, a drug that opens potassium channels in the brain, may be associated with an improvement in depressive symptoms.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/petrusraulino.com.br\/en\/potassium-ion-channel-modulation-for-the-treatment-of-depression\/","og_locale":"en_US","og_type":"article","og_title":"Modula\u00e7\u00e3o do canal i\u00f4nico de pot\u00e1ssio para tratamento da depress\u00e3o?","og_description":"Estudo mostra que ezogabina, um f\u00e1rmaco que abre canais de pot\u00e1ssio no c\u00e9rebro, pode estar associada \u00e0 melhora de sintomas depressivos.","og_url":"https:\/\/petrusraulino.com.br\/en\/potassium-ion-channel-modulation-for-the-treatment-of-depression\/","og_site_name":"Dr. Petrus Raulino","article_publisher":"https:\/\/www.facebook.com\/drpetrusraulinopsiquiatriaclinica","article_published_time":"2021-06-08T18:00:37+00:00","article_modified_time":"2024-11-11T20:19:50+00:00","og_image":[{"width":1447,"height":868,"url":"https:\/\/petrusraulino.com.br\/wp-content\/uploads\/2021\/06\/modulacao.jpg","type":"image\/jpeg"}],"author":"Dr. Petrus Raulino","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Petrus Raulino","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[]}},"_links":{"self":[{"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/posts\/1465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/comments?post=1465"}],"version-history":[{"count":1,"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/posts\/1465\/revisions"}],"predecessor-version":[{"id":45251,"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/posts\/1465\/revisions\/45251"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/media\/1478"}],"wp:attachment":[{"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/media?parent=1465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/categories?post=1465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/petrusraulino.com.br\/en\/wp-json\/wp\/v2\/tags?post=1465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}